The pharmaceutical startup Synthetic Biologics Inc. (NYSE Amex: SYN) reported a larger loss for the year ended Dec. 31, but also a host of promising operational highlights.
Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.
Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had started a Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis in women.
Adeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.
Ann Arbor-based Adeona Pharmaceuticals Inc. announced Tuesday that after a scientific review, the ongoing clinical trial of its Trimesta oral estriol drug for multiple sclerosis has eeceived an additional $1,594,553 in grant funding from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke.
Ann Arbor-based Adeona Pharmaceuticals Inc. said Monday that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.